Quantcast

Latest pulmonary function testing Stories

2014-09-10 12:24:27

RIDGEFIELD, Conn., Sept. 10, 2014 /PRNewswire/ -- In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Pharmaceuticals, Inc., announces the airing of Every Breath Counts: Idiopathic Pulmonary Fibrosis -- a documentary supported by the company and created in collaboration with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis in an effort to increase awareness and understanding of idiopathic pulmonary fibrosis (IPF) among the general public....

2014-09-08 12:30:18

Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD, Conn., Sept. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented the first data from the pivotal Phase III TONADO(TM) 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium plus olodaterol delivered via the Respimat(®) inhaler in patients with moderate to...

2014-09-08 08:29:55

-- LANTERN study met primary endpoint demonstrating non-inferiority of Ultibro® Breezhaler® 110/50 mcg vs Advair* Diskus* (SFC) 50/500 mcg followed by statistically significant superiority in post dose trough FEV1 after 26 weeks of treatment in patients with moderate-to-severe COPD1 -- In addition, LANTERN study met an endpoint demonstrating that Ultibro®Breezhaler ® reduced...

2014-08-19 12:28:32

For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat(®) inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including...

2014-08-11 08:28:18

PARIS and VALENCIA, Calif., Aug. 11, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Under...

2014-07-29 12:35:21

WARRINGTON, Pa., July 29, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report its second quarter 2014 financial results on August 5, 2014 before the open of the U.S. financial markets. The Company will host a live teleconference and webcast at 9:00 a.m. Eastern Time that same day. During the conference call, Discovery Labs' management will discuss the...

2014-07-24 08:31:52

ANDOVER, Mass., July 24, 2014 /PRNewswire/ -- ndd Medical Technologies, a leader in innovative mobile pulmonary function testing (PFT) employing precise ultrasound technology, announced that its EasyOne Pro(®) has been chosen as the instrument to measure Carbon Monoxide Diffusing Capacity (DLCO) for phase 2 of the COPDGene(®) Study, the most comprehensive study of Chronic Obstructive Pulmonary Disease (COPD) ever undertaken. COPD is now the third leading cause of death in the U.S....

2014-07-01 11:31:24

American Thoracic Society In a new study of the causes underlying respiratory symptoms in military personnel returning from duty in Iraq and Afghanistan, a large percentage of veterans had non-specific symptoms that did not lead to a specific clinical diagnosis. Most patients who did receive a diagnosis had evidence of asthma or nonspecific airway hyperreactivity, which may have been due in some cases to aggravation of pre-existing disease by deployment exposures. "Earlier studies of...

2014-06-25 23:08:06

Measuring home spirometry combined with administration of ACQ and/or EXACT-PRO increases data reliability while reducing trial costs. Philadelphia (PRWEB) June 25, 2014 ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced that its AM3® meter is the only integrated home spirometer and electronic Diary (eDiary) authorized to implement the most commonly used standardized instruments for both asthma and chronic...

2014-06-17 08:29:40

WARRINGTON, Pa., June 17, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has been awarded the final $1.9 million of a $2.4 million Fast Track Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). This award will provide support for the ongoing phase 2a clinical trial for AEROSURF®, Discovery Labs' investigational combination drug/device product....


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related